Alligator Bioscience AB (publ) (STO:ATORX)

Market Cap	106.53M -20.2%
Revenue (ttm)	4.42M -92.3%
Net Income	-51.35M
EPS	-1.87
Shares Out	628.11M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,582,852
Average Volume	4,389,323
Open	0.1730
Previous Close	0.1720
Day's Range	0.1685 - 0.1735
52-Week Range	0.1678 - 7.6000
Beta	1.20
RSI	37.78
Earnings Date	May 5, 2026

About Alligator Bioscience AB

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Finland and Sweden. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage for the treatment of solid metastatic tumors. It also offers...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 11
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ATORX

Financial Performance

In 2025, Alligator Bioscience AB's revenue was 4.42 million, a decrease of -92.34% compared to the previous year's 57.72 million. Losses were -51.35 million, -78.05% less than in 2024.